Delving into the Latest Updates on Curia Massachusetts, Inc. with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Nervous System Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

GR(Glucocorticoid receptor)	1

To evaluate the efficacy and safety of dexamethasone implant in the treatment of post-cataract surgery inflammation, to evaluate the pharmacokinetic characteristics of dexamethasone implant in subjects with post-cataract surgery inflammation after administration, and to assess the ease of use, duration of use, and safety of dexamethasone implant pusher.

Start Date21 Jul 2022

Sponsor / Collaborator

EyePoint Pharmaceuticals, Inc.

[+2]

CTR20160128 / TerminatedPhase 3

评价ThermoDox联合标准化射频消融治疗单个病灶肝细胞癌的双盲、随机、安慰剂对照的多中心研究

[Translation] A double-blind, randomized, placebo-controlled, multicenter study evaluating ThermoDox combined with standardized radiofrequency ablation for the treatment of single-lesion hepatocellular carcinoma

主要目的是使用标准化射频消融（sRFA），治疗驻留时间不少于45分钟，比较接受RFA联合ThermoDox治疗相对于仅RFA治疗病人之间的总生存期。次要目的是用标准化治疗驻留时间不少于45分钟，比较接受sRFA联合ThermoDox相对于单独sRFA治疗的病人之间的无进展生存期以及安全性。

[Translation]

The primary objective was to compare overall survival between patients who received RFA plus ThermoDox versus RFA alone, using standardized radiofrequency ablation (sRFA) with a treatment dwell time of ≥45 minutes. Secondary objectives were to compare progression-free survival and safety between patients who received sRFA plus ThermoDox versus sRFA alone, using a standardized treatment dwell time of ≥45 minutes.

Start Date19 Apr 2016

Sponsor / Collaborator

Linical Accelovance China Ltd

[+2]

100 Clinical Results associated with Curia Massachusetts, Inc.

Login to view more data

0 Patents (Medical) associated with Curia Massachusetts, Inc.

Login to view more data

100 Deals associated with Curia Massachusetts, Inc.

Login to view more data

100 Translational Medicine associated with Curia Massachusetts, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Dexamethasone ( GR )	Post procedural inflammation More	NDA/BLA
Doxorubicin liposomal ( DNA x Reactive oxygen species x Top II )	Hepatocellular Carcinoma More	Discontinued